APA (7th ed.) Citation

Yang, Y., Sun, J., Wang, Z., Fang, J., Yu, Q., Han, B., . . . Zhang, L. (2020). LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Annals of Oncology, 31, S1186. https://doi.org/10.1016/j.annonc.2020.08.2290

Chicago Style (17th ed.) Citation

Yang, Y., et al. "LBA57 MHC-II Antigen Presentation Pathway as a Predictive Biomarker for Sintilimab Plus Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (nsq-NSCLC)." Annals of Oncology 31 (2020): S1186. https://doi.org/10.1016/j.annonc.2020.08.2290.

MLA (9th ed.) Citation

Yang, Y., et al. "LBA57 MHC-II Antigen Presentation Pathway as a Predictive Biomarker for Sintilimab Plus Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (nsq-NSCLC)." Annals of Oncology, vol. 31, 2020, p. S1186, https://doi.org/10.1016/j.annonc.2020.08.2290.